No that's a fair question. Most stocks were oversold (dare I say all?) on original covid panic, and maybe even a snowball effect happened here: stop losses, cashing out from people becoming unemployed, you name it.
some recovery and fiscal stimulus helped the economy in general. Prior to covid it was just business as usual but we were seeing above $3. So now for us, fundamentally, nothing had changed, but we now have a crack at a treatment for pandemic stricken people. A new blockbuster product has appeared! in conjunction with mild recovery, this was priced in (above $4 prior to asx200 inclusion, noting that analysts are still targeting $6~ during this time). Why we have dipped to where we have now? I'll leave that up to someone else to address.
Ann: EAP for Remestemcel-L in Children with MIS-C due to COVID-19, page-227
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.045(4.07%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.16 | $1.08 | $4.681M | 4.170M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99680 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 31000 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |